

## Intercell 2010 Annual Shareholders Meeting - All Resolutions Approved

*Report on the annual shareholders meeting and announcement according to Para 82 Section 9 Austrian Stock Exchange Act in connection with Para 2 Section 1 and Para 3 Section 1 Publication Directive regarding the authorization to repurchase own shares*

**Vienna, June 25, 2010** – Intercell AG (Vienna Stock Exchange, ICLL) today announced that all proposed resolutions were approved by the Annual Shareholders Meeting held today. A total of approximately 33% of the outstanding share capital of Intercell AG was represented in the meeting.

Authorization to repurchase own shares: The unused authorization of the management board granted by a resolution of the annual general meeting held on June 13, 2008 to repurchase treasury bearer shares within a duration of 30 months from the date of that resolution at a minimum equivalent of Euro 20.00 per share and a maximum equivalent of Euro 60.00 per share of choice of the management board on the stock exchange or through a public offer is revoked. Simultaneously the management board is authorized according to section 65 para 1 subpara 8 of the Stock Corporation Act (AktG) to repurchase within the legal limits treasury shares with no par value within a duration of 30 months from the date of this resolution at a minimum equivalent of Euro 12.00 per share and a maximum equivalent of Euro 60.00 per share. a) The management board is authorized to use treasury shares to serve stock options granted to employees, executives and members of the management board of the Company or an affiliated company and/or members of the supervisory board of the company or an affiliated company, b) to sell treasury shares in accordance with section 65 para 1 b Stock Corporation Act (AktG) at any time via the stock exchange or by a public offer, or c) with the consent of the supervisory board to resolve on another way of selling of the treasury shares than on the stock exchange or by a public offer under exclusion of the subscription rights of existing shareholders.

The further resolutions included:

- » Discharge of the members of the management board for the business year 2009.
- » Discharge of the members of the supervisory board for the business year 2009.
- » Remuneration for the members of the supervisory board for the business year 2009.
- » Providing for the grant of stock options as remuneration to members of the Company's supervisory board.
- » Election of the auditor and the group auditor for the business year 2010.
- » Resolution on the amendments to the Articles of Association reflecting the Aktienrechtsaenderungsgesetz 2009 (Stock Corporation (Amendment) Act 2009).

At the meeting Intercell's Management Team (CEO Gerd Zettlmeissl, CFO Reinhard Kandra and COO Thomas Lingelbach) reported on the business year 2009 including the financial



results and presented an overview on the business strategy and recent achievements in 2010. The presentation to the shareholders is available at the company's website [www.intercell.com](http://www.intercell.com).

For further details about the resolutions please see [www.intercell.com](http://www.intercell.com).

## **About Intercell AG**

Intercell AG is an innovative biotechnology company that develops novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical needs. Intercell's vaccine to prevent Japanese Encephalitis is the Company's first product on the market.

The Company's technology platform includes an antigen-discovery system and human anti-infective monoclonal antibody discovery system, adjuvants and a novel patch-based delivery system (Vaccine Patch, Vaccine Enhancement Patch). Based on these technologies, Intercell has strategic partnerships with a number of global pharmaceutical companies, including GSK, Novartis, Merck & Co., Inc., sanofi-aventis, and Pfizer (formerly Wyeth).

The Company's pipeline of investigational products includes a Travelers' Diarrhea Vaccine Patch (Phase III), a Pseudomonas vaccine candidate (Phase II), a vaccine to prevent Pandemic Influenza combining our Vaccine Enhancement Patch with an injected vaccine (Phase II), a vaccine program for S. aureus, which is being developed with Merck & Co., Inc. (Phase II/III), as well as a vaccine candidate for Pneumococcus (Phase I). In addition, further products focused on infectious diseases are in pre-clinical development.

Intercell is listed on the Vienna stock exchange under the symbol "ICLL" (U.S. level one ADR symbol "INRLY").

For more information, please visit: [www.intercell.com](http://www.intercell.com)

## **Contact**

### **Intercell AG**

Lucia Malfent

Global Head of Corporate Communications

Campus Vienna Biocenter 3, A-1030 Vienna

P: +43-1-20620-1303

Mail to: [LMalfent@intercell.com](mailto:LMalfent@intercell.com)

*This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*